XOMA Royalty Corp
XOMAONasdaq
$25.00
0.0%Jul 17 close · end-of-day
Price
1Y↑ +6.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$435.4M
Enterprise Value
$452.7M
P/E
15.9
P/S
9.0
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$48.6M
Net Income (TTM)
$33.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
10.3%
Net Margin
69.6%
ROE
36.4%
ROIC
3.6%
Debt / Equity
1.1
Net Cash
-$17.2M
Return 1Y
+6.0%
Company profile
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets with commercial sales potential.
- CEO
- James R. Neal, EMBA
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- xoma.com
Earnings
XOMAO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.3M↓ -22.6%
Diluted EPS$0.17↑ +183.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $29.4M | $38.2M | $6.0M | $4.8M | $28.5M | $52.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $12.4M | $17.5M | -$17.4M | -$41.8M | -$40.0M | $11.4M |
| Net income | $13.3M | $15.8M | -$17.1M | -$40.8M | -$13.8M | $31.7M |
| Diluted EPS | $0.78 | $0.65 | -$1.98 | -$4.04 | -$1.65 | $1.46 |
| Operating cash flow | $10.1M | $22.7M | -$12.9M | -$18.2M | -$13.7M | $2.9M |
| Free cash flow | $10.1M | — | — | -$18.2M | -$13.8M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 42.3% | 45.9% | -288.9% | -879.5% | -140.3% | 21.8% |
| Net margin | 45.3% | 41.4% | -283.8% | -858.2% | -48.5% | 60.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1M | $7.2M | $8.7M | $15.9M | $13.1M | $9.4M | $13.8M | $12.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.1M | -$15.6M | -$7.3M | $5.9M | $4.6M | -$1.3M | $2.2M | -$480,000.00 |
| Net income | $16.0M | -$17.2M | -$4.0M | $2.4M | $9.2M | $14.1M | $6.1M | $4.5M |
| Diluted EPS | $0.84 | -$1.59 | -$0.04 | $0.06 | $0.44 | $0.70 | $0.26 | $0.17 |
| Operating cash flow | $2.7M | -$8.6M | -$2.9M | $2.2M | $6.5M | -$296,000.00 | -$5.5M | $6.1M |
| Free cash flow | $2.7M | -$8.6M | -$2.9M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -90.9% | -217.3% | -83.2% | 37.3% | 35.1% | -14.2% | 15.9% | -3.9% |
| Net margin | 144.2% | -239.6% | -45.5% | 14.9% | 70.0% | 150.3% | 44.4% | 36.2% |
Company news
Jul 14, 2026
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.